Abstract: Devices and methods for treating obstructive sleep apnea by first performing an assessment of the patient that involves observing the patient's upper airway during a tongue protrusion maneuver. The assessment may, for example, be done using endoscopy to observe the upper airway while the patient is awake in the supine position. An adequate response of the upper airway during the tongue protrusion maneuver is indicative of likely therapeutic success with hypoglossal nerve stimulation, and may be used for making clinical decisions. The principles of the present invention may be applied to other therapeutic interventions for OSA involving the upper airway.
Type:
Application
Filed:
January 27, 2017
Publication date:
July 20, 2017
Applicant:
Cyberonics, Inc.
Inventors:
Wondimeneh TESFAYESUS, Stephen L. BOLEA, Peter R. EASTWOOD, David R. HILLMAN
Abstract: A method includes determining sleep cycle information related to a sleep cycle of a patient based on body parameter data. The method also includes adjusting a cranial nerve stimulation parameter based on the sleep cycle information.
Abstract: Methods, systems, and apparatus for detecting the seizure in a patient using a medical device. The determination is performed by collecting cardiac data; determining valid heart beats suitable for seizure detection from the cardiac data; calculating heart rate data of interest from the valid heart beats; and identifying a seizure event from the heart rate data. The medical device may then take a responsive action, such as warning, logging the time of the seizure, computing and storing one or more seizure severity indices, and/or treating the seizure.
Abstract: A method includes receiving heartbeat data of a patient and receiving activity data of the patient. The activity data includes one or more activity values that are related to an activity level of the patient and that are measured independently of the heartbeat data. The method further includes determining a value of a weighting factor based on the activity data. The method also includes determining modified heartbeat data by applying the weighting factor to at least a portion of the heartbeat data. The method also includes detecting a seizure event based on the modified heartbeat data.
Abstract: Methods, systems, and apparatuses for detecting seizure events are disclosed, having at least one accelerometer to be positioned on a patient and configured to collect acceleration data and a processor in communication with the at least one accelerometer and configured to receive acceleration data from the at least one accelerometer. The processor may apply at least one non-linear operator to the acceleration data to determine whether the acceleration data indicates an event, such application including calculation of a non-linear energy of the acceleration data and performance of at least one secondary analysis to determine whether the event is a seizure.
Abstract: An isolated circuit including a RF input configured to receive a far field radiative powering signal and a rectified voltage output configured to provide a rectified voltage based on the received far field radiative powering signal. The isolated circuit also includes a first power assembly comprising a first impedance coupled to the RF input where the first impedance is provided, at least in part, by activating a first switch in response to the rectified voltage satisfying a first voltage threshold. The isolated circuit also includes a second power assembly comprising a second impedance coupled to the RF input where the second impedance is provided, at least in part, by activating the first switch and a second switch in response to the rectified voltage satisfying the first voltage threshold and a second voltage threshold, respectively.
Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A neural fulcrum zone is identified and ongoing neurostimulation therapy is delivered within the neural fulcrum zone. This neural fulcrum zone corresponds to a combination of stimulation parameters at which autonomic engagement is achieved, while the tachycardia-inducing stimulation effects are offset by the bradycardia-inducing effects, thereby minimizing side effects such as significant heart rate changes while providing a therapeutic level of stimulation.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
June 6, 2017
Assignees:
CYBERONICS, INC., EAST TENNESSEE STATE UNIVERSITY
Inventors:
Bruce H. KenKnight, Jeffrey L. Ardell, Imad Libbus, Badri Amurthur
Abstract: A system for providing alerts of neurological events occurring in a human subject is provided. The system includes: a monitoring module adapted to detect and sample a neurological signal; an event detection module coupled to the monitoring module for detecting one or more types of predetermined reportable events based on the detected neurological signal; and an alert module coupled to the event detection module, wherein upon the detection of a reportable event by the event detection module, said alert module selects a first alert contact from a plurality of contacts contained in a contact list, and generates a first alert communication to the first alert contact.
Type:
Grant
Filed:
February 14, 2011
Date of Patent:
May 9, 2017
Assignee:
CYBERONICS, INC.
Inventors:
Jason A. Higgins, Michael Bland, Kent W. Leyde, W. Douglas Sheffield, John F. Harris, David M. Himes
Abstract: A patient suffering from congestive heart failure is at increased risk of cardiac arrhythmogenesis during sleep, particularly if experiencing central sleep apnea as a co-morbidity. Low intensity peripheral neurostimulation therapies that target imbalance of the autonomic nervous system have been shown to improve clinical outcomes. Thus, bi-directional autonomic regulation therapy is delivered to the cervical vagus nerve at an intensity that is insufficient to elicit pathological or acute physiological side effects and without the requirement of an enabling physiological feature or triggering physiological marker. The patient's physiology is monitored to identify periods of sleep. In one embodiment, upon sensing a condition indicative of tachyarrhythmia following a period of bradycardia, as naturally occurs during sleep, an enhanced “boost” dose of bi-directional neural stimulation intended to “break” the tachyarrhythmic condition is delivered.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
May 9, 2017
Assignee:
CYBERONICS, INC.
Inventors:
Imad Libbus, Badri Amurthur, Bruce H. Kenknight
Abstract: An implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers including a patient's cervical vagus nerve. An operating mode is stored in the pulse generator. An enhanced dose of the electrical therapeutic stimulation is parametrically defined and tuned to prevent or disrupt tachyarrhythmia through continuously-cycling, intermittent and periodic electrical pulses. The patient's physiological state is monitored during physical exercise via at least one sensor included in the implantable neurostimulator, and upon sensing a condition indicative of cessation of the physical exercise, the enhanced dose is delivered for a period of time the enhanced dose to the vagus nerve.
Type:
Grant
Filed:
November 9, 2012
Date of Patent:
May 9, 2017
Assignee:
CYBERONICS, INC.
Inventors:
Imad Libbus, Badri Amurthur, Bruce H. KenKnight
Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients for treating chronic heart failure. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. This titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.
Type:
Application
Filed:
December 30, 2016
Publication date:
April 20, 2017
Applicant:
Cyberonics, Inc.
Inventors:
Imad LIBBUS, Bruce H. KENKNIGHT, Badri AMURTHUR
Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients. A titration process is used to gradually increase the stimulation intensity to a desired therapeutic level. Between titration sessions one or more parameters, such as, for example, an acclimation interval, may be adjusted based on the patient's response to the stimulation. This personalized titration process can minimize the amount of time required to complete titration so as to begin delivery of the stimulation at therapeutically desirable levels.
Type:
Application
Filed:
November 23, 2016
Publication date:
April 20, 2017
Applicant:
CYBERONICS, INC.
Inventors:
Imad Libbus, Bruce H. KenKnight, Badri Amurthur, Scott R. Stubbs
Abstract: Systems and methods for monitoring neurological signals in a patient are provided. The system includes: an implantable sensor adapted to collect neurological signals; an implantable assembly configured to sample the neurological signals collected by the sensor; and a rechargeable communication device external to the patient's body, said communication device configured to wirelessly communicate with the implantable assembly and to transmit a communication error alert to a caregiver advisory device in the event of a communication error between the implantable assembly and the communication device.
Abstract: An implantable neurostimulator-implemented method for managing tachyarrhythmias through vagus nerve stimulation is provided. An implantable neurostimulator, including a pulse generator, is configured to deliver electrical therapeutic stimulation in a manner that results in creation and propagation (in both afferent and efferent directions) of action potentials within neuronal fibers of a patient's cervical vagus nerve. Operating modes of the pulse generator are stored. A maintenance dose of the electrical therapeutic stimulation is delivered to the vagus nerve via the pulse generator to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses. A restorative dose of the electrical therapeutic stimulation is delivered to prevent initiation of or disrupt tachyarrhythmia through periodic electrical pulses delivered at higher intensity than the maintenance dose.
Type:
Application
Filed:
September 23, 2016
Publication date:
April 13, 2017
Applicant:
CYBERONICS, INC.
Inventors:
Imad Libbus, Badri Amurthur, Bruce H. KenKnight
Abstract: Systems and methods are provided for delivering neurostimulation therapies to patients. Stimulation from an implantable medical device (IMD) may be suspended in response to detecting a patient discomfort event, such as a cough, throat irritation, or voice alteration. The suspension period may be based on at least one of a severity level of the patient discomfort event and a patient physical state, such as being asleep or lying down. Detection of a patient discomfort event may be calibrated.
Type:
Application
Filed:
October 4, 2016
Publication date:
April 6, 2017
Applicant:
CYBERONICS, INC.
Inventors:
Imad LIBBUS, Scott R. STUBBS, Bruce H. KENKNIGHT
Abstract: The system, device, and method may use electrical stimulation of the vagus nerve to treat epilepsy with minimized or no effect on the heart. Treatment is carried out by an implantable signal generator, one or more implantable electrodes for electrically stimulating a predetermined stimulation site of the vagus nerve, and a sensor for sensing characteristics of the heart such as heart rate. The heart rate information from the sensor can be used to determine whether the vagus nerve stimulation is adversely affecting the heart. Once threshold parameters are met, the vagus nerve stimulation may be stopped or adjusted. In yet another embodiment, the system, device, and method may be simply a modified pacemaker having circuitry that determines whether a vagus nerve is being stimulated. In the event that the vagus nerve is being stimulated, the modified pacemaker may control the heart to maintain it within desired conditions during the vagus nerve stimulation.
Abstract: The present invention provides systems and methods for managing epilepsy. In one embodiment, a method of the present invention characterize a patient's propensity for a future epileptic seizure and communicates to the patient and/or a health care provider a therapy recommendation. The therapy recommendation is typically a function of the patient's propensity for the future epileptic seizure.
Abstract: Disclosed are methods and systems for treating epilepsy by stimulating a main trunk of a vagus nerve, or a left vagus nerve, when the patient has had no seizure or a seizure that is not characterized by cardiac changes such as an increase in heart rate, and stimulating a cardiac branch of a vagus nerve, or a right vagus nerve, when the patient has had a seizure characterized by cardiac changes such as a heart rate increase.
Abstract: A method includes receiving heartbeat data of a patient and receiving activity data of the patient. The activity data includes one or more activity values that are related to an activity level of the patient and that are measured independently of the heartbeat data. The method further includes determining a value of a weighting factor based on the activity data. The method also includes determining modified heartbeat data by applying the weighting factor to at least a portion of the heartbeat data. The method also includes detecting a seizure event based on the modified heartbeat data.
Abstract: Devices and methods for treating obstructive sleep apnea by first performing an assessment of the patient that involves observing the patient's upper airway during a tongue protrusion maneuver. The assessment may, for example, be done using endoscopy to observe the upper airway while the patient is awake in the supine position. An adequate response of the upper airway during the tongue protrusion maneuver is indicative of likely therapeutic success with hypoglossal nerve stimulation, and may be used for making clinical decisions. The principles of the present invention may be applied to other therapeutic interventions for OSA involving the upper airway.
Type:
Grant
Filed:
July 20, 2015
Date of Patent:
January 31, 2017
Assignee:
CYBERONICS, INC.
Inventors:
Wondimeneh Tesfayesus, Stephen L. Bolea, Peter R. Eastwood, David R. Hillman